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Clinical decision support systems (CDSS) aid health care professionals (HCP) in
evaluating large sets of information and taking informed decisions during their clinical
routine. CDSS are becoming particularly important in the perspective of precision
medicine, when HCP need to consider growing amounts of data to create precise
patient profiles for personalized diagnosis, treatment and outcome monitoring. In
allergy care, several CDSS are being developed and investigated, mainly for respiratory
allergic diseases. Although the proposed solutions address different stakeholders, the
majority aims at facilitating evidence-based and shared decision-making, incorporating
guidelines, and real-time clinical data. We offer here an overview on existing tools, new
developments and novel concepts and discuss the potential of digital CDSS in improving
prevention, diagnosis and monitoring of allergic diseases.
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THE EVOLUTION OF CLINICAL DECISION SUPPORT SYSTEMS
IN THE CONTEXT OF PRECISION MEDICINE
Origins of Digital Clinical Decision Support
Researchers and engineering technologists have been developing and exploring computerized
decision support systems (DSS) for approximately 50 years (1). In their early stages, DSS were
categorized according to their methodology, ranging from data-oriented approaches, whose
systems merely extracted information, to model-oriented concepts, mostly focused on decision
processes. Alongside technological advances, this kind of computerized tool became increasingly
powerful and elaborated, offering solutions for the processing of complex data sets and their
integration in decision algorithms providing data-driven suggestions to the user (2). The ability
to capture expert knowledge, guidelines and reasoning techniques, together with the automation of
rules via identification of key attributes led to the development of new digital support opportunities
for healthcare providers in their clinical routine (3).
Abbreviations: AH, antihistamines; AIT, allergen-specific immunotherapy; AMA, American medical association; AMSS,
allergy management support system; AR, allergic rhinitis; ARIA, allergic rhinitis and its impact on asthma; CDSS, clinical
decision support system; COPD, chronic obstructive pulmonary disease; DSS, decision support system; eAMS, electronic
Asthma Management System; EHR, electronic health record; GP, general practitioner; HCP, health care professionals; INCS,
intranasal corticosteroids; PDSS, pharmacy decision support system; VAS, Visual Analogue Scale.
Frontiers in Immunology | www.frontiersin.org 1 September 2020 | Volume 11 | Article 2116
fimmu-11-02116 September 8, 2020 Time: 18:14 # 2
Dramburg et al. CDSS for Allergy Care
Methodologies
The development of computerized clinical support tools can
be grouped according to the following main methodologies:
(a) information retrieval tools to answer clinical questions and
manage medical information (4); (b) logical models for the
assignment of categories for medical standard measurements (5),
characterized alerts and reminder systems (6); (c) probabilistic
and data-driven prediction algorithms to improve patient
outcomes (7); and (d) a modeled combination of formal and
heuristic algorithms supporting physicians in their decision on
the individual deployment of evidence-based solutions (8, 9).
Today, these methodologies carry the potential of becoming an
innovative resource for digital augmentation of clinical care, once
scientifically and clinically validated. To ensure patient safety,
technologies with a potential impact on medical decisions need
to undergo the registration and certification process for medical
devices at the respective regulatory authorities (10, 11).
Advantages of Digital Decision Support
Due to the growing amount of health data, delivering
personalized precision medicine has become a challenging
task (12). Large sets of information are not only derived
from complex diagnostic test systems, genetic analyses and –
omics approaches, but also patient-generated monitoring data,
exposure information and/or the surveillance of physiological
parameters via smart devices and sensors (13). In parallel,
electronic health records (EHR) have become a common
platform to bundle patient data and clinical decision support
systems (CDSS) are frequently connected to these critical
information hubs (6). This is where trained algorithms and
validated computerized tools can assist health care professionals
(HCP) in efficiently interpreting complex data sets and keeping
the overview on the individual health status of a patient (14).
Automated monitoring and alerts systems further enable a
continuous personalized treatment follow-up and allow an early
intervention in the case of side effects or insufficient success.
Challenges and Limitations of Clinical
Decision Support
Although digital decision support tools can be potentially
useful in optimizing clinical workflows, it is important to
mention that they are by no means able to replace a trained
healthcare professional. In addition, several challenges need to
be considered. Clinical work often includes hectic situations
and a broad spectrum of patients with different conditions,
comorbidities, and treatment plans being treated by one doctor.
Therefore, a support tool needs to be extraordinarily user-
friendly, ideally adaptable to individual settings with a high
level of interoperability and include a solid risk management
as any medical device. Apart from technical challenges like an
optimal human-computer interface there are particular aspects
to be addressed within different methodologies (1). To give an
example: alert systems with an high alert frequency (e.g., for
potential drug interactions) may cause a alert fatigue in the user,
who may decide more frequently to disregard the suggestions.
As the user is a trained professional, this may not seem crucial
at first sight. However, a negative impression of fatigue may
lead to an adverse predisposition toward other, potentially more
user-friendly, technologies. This example reflects the diversity of
challenges, which need to be considered in the development of
decision support tools. They are not only of technical nature but
also related to adoption by different stakeholders and integration
into a broad spectrum of pre-existing settings.
Adoption of Decision Support
Technologies by Health Care
Professionals
The prospective collection of clinical and diagnostic data
provides valuable insights into disease endo- and phenotypes
and has the potential to offer distinct advantages in the field
of chronic diseases such as allergy and asthma (15). Digital
technologies potentially allow continuous disease monitoring
with agile adaptation strategies decided on by the physician to
improve patient outcomes and quality of life, especially as part
of a chronic disease management process. However, physicians
are core to the medical decision process and accountable for
their choices. If computer algorithms are aiding these, reliability
and accountability are key elements to be addressed prior to a
widespread adoption of any digital solution. This challenge may
be one of the reasons for low adoption rates for new digital
tools in clinical routine (16), although recent data from the
American Medical Association show an increased interest among
physicians in digital support tools (from 28% in 2016 to 37%
in 2019) (17). The category CDSS in this assessment included
any modules and integrated mobile applications in conjunction
with EHR, also enabling the remote monitoring of patient-
related parameters and automated integration of the results in the
central data set. Interestingly, the adoption rates for monitoring
tools alone, without integration in a CDSS, increased from 12%
(2016) to 16% (2019) for remote efficiency monitoring and from
13% (2016) to 22% (2019) for remote management tools for
chronically ill patients (17) (Figure 1). It has to be stated, though,
that reported use does not necessarily reflect any improvement
of patient outcomes (18). In order to enable a critical evaluation
and smooth implementation of new tools in healthcare systems,
it is important to ensure that professionals are adequately trained
on the benefits and challenges of CDSS before applying them in
clinical practice (9).
CLINICAL DECISION SUPPORT FOR
ALLERGIC DISEASES
Allergic diseases are clinically and immunologically multifaceted,
as well as pathogenetically heterogenous (15), which makes an
evidence-based clinical diagnosis rather challenging. Moreover,
the ratio of allergists per allergic patient is in general rather
low and highly heterogenous in different countries (19, 20). As
a first point of contact, most allergic patients see a primary
care doctor, who frequently lacks the knowledge, confidence or
resources to meet their specific needs due to insufficient training
(21). Independently from the individual level of specific training,
clinicians are confronted with a broad spectrum of clinical
manifestations, such as allergic rhinitis (AR), asthma, atopic
eczema, food allergies, anaphylaxis, drug allergies or occupational
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FIGURE 1 | The use of digital health tools among United States physicians in 2016 and 2019. The survey has been performed by the American Medical Association
(AMA) among 1300 (1359 respectively) physicians working in different clinical settings. © 2020 American Medical Association. Reprinted with Permission [17].
https://www.ama-assn.org/.
allergies, whose pathogenesis is heterogeneous. In addition, the
nomenclature and classification of these allergic diseases is being
challenged (22, 23) and the guidelines for diagnostic work-ups
change over time (24, 25) or differ between different regions
(26, 27).
In this context, computerized decision support concepts are
becoming a potentially valuable tool to support clinicians in
evaluating large data sets and taking into account complex
guidelines. Electronic health (eHealth) technologies, especially
mobile health (mHealth) tools, have become more and more
popular and provide valuable clinical information on patients.
However, tools merely providing information without concrete
suggestions for diagnostic and therapeutic decisions should not
be considered a CDSS. The software tools and mobile solutions
discussed here have the potential to enhance medical decisions at
the point-of-care mainly with (A) targeted patient information,
(B) guideline- and evidence-based clinical knowledge, and
(C) prospectively collected data (patient-/sensor-generated).
A positive effect of clinical decision support on the practitioner’s
performance has already been shown for several chronic health
conditions (28–31). However, more studies are needed to assess
the impact on short, medium-, and long-term patient outcomes.
In allergy care, several concepts for CDSS have been created,
addressing different diseases and settings with the aim of
improving detection, diagnosis and diseases management (32,
33). In most cases, the main target is to empower not only
the allergist, but also the general practitioners (GPs) and even
the patient, at public contact points such as pharmacies. The
following paragraphs will give an overview on existing solutions,
concepts and potentials for future developments.
DECISION SUPPORT SYSTEMS FOR THE
MANAGEMENT OF ALLERGIC RHINITIS
Developments of the Allergy and Its
Impact on Asthma (ARIA) Consortium
Several expert groups have elaborated algorithms and support
tools to facilitate screening, diagnostic precision, early
optimization of therapy and user-friendly monitoring of
chronic respiratory allergic diseases. Among these, the ARIA
consortium elaborated a detailed decision algorithm based on
clinical scenarios for AR patients treated with symptomatic
drugs. The development process involved a key opinion leader
consensus on specific treatment recommendations, which has
been published transparently (34). The authors count on a
broad experience on the collection of symptom data via mobile
health technology (35–37) in which the CDSS is planned to be
integrated. However, the system is not yet publicly available
online and publications on its implementation are expected to
be published soon.
DSS in the Pharmacy
Another ARIA initiative to provide front-line decision support
has been proposed to implement integrated care pathways
for AR at the level of community pharmacies (37). Patients
suffering from AR often self-medicate with over-the-counter-
drugs with correspondingly poor results (38); hence, pharmacists
assume an important role in the care pathway for patients
suffering from respiratory allergies (39). An open intervention
study among German pharmacists revealed that pharmacists
failed to ask several questions essential to make a diagnosis,
confirm the appropriateness of self-medication and the drug
choice (40). When implementing a pharmacist decision support
system (PDSS), the pharmacists asked seven (78%; IQR 5.25–
9) instead of two (22%; IQR 1–3) of the nine required
questions. The use of the PDSS resulted in a significant
improvement of patient evaluation and required only 1.5 min
(40). Notwithstanding its limitations, this study pioneers the
implementation of a DSS for AR symptomatic treatment
at pharmacy level. The ARIA consortium also underlined
the importance of pharmacists for integrated care pathways
of respiratory allergic diseases (41). The authors recently
proposed a CDSS supporting pharmacists in monitoring
the patient’s symptom control and adjusting symptomatic
treatment accordingly (42) (Figure 2). This comprehensive
approach to supporting pharmacists in their front-line role
in allergy care is a promising concept. The evaluation or
validation of the system in a real-life setting is therefore a
research priority.
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FIGURE 2 | Decision algorithm for treatment of allergic rhinitis in the pharmacy. AH, antihistamine; INAH, intranasal antihistamine; INCS, intranasal corticosteroid;
IOAH, intraocular antihistamine. *INCS if coexisting asthma. Visual Analogue Scale (VAS) nose/eye: “How much are your nose/eye symptoms bothering you today?”
(0 = not at all bothersome, 10 = extremely bothersome). Adapted from Tan et al. (38).
CDSS for Allergen Immunotherapy
A different concept has been followed in the development
of a support system facilitating the precise prescription of
allergen-specific immunotherapy (AIT), i.e., the only disease-
modifying treatment for AR (33). Decision support for AIT
prescription is particularly valuable in geographic areas with high
rates of poly-sensitization and overlapping flowering periods of
many allergenic plants; in these areas the distinction between
genuine and cross-reactive sensitization is extremely difficult
and the precise identification of the pollen causing allergic
symptoms is crucial for AIT efficacy (43, 44). The traditional
diagnostic approach, based on a retrospective clinical history
and extract-based skin prick or IgE testing, is suboptimal due
to several reasons. On one hand, the clinical history can be
unreliable due to a recall bias, especially when seasonal symptoms
occurred several months before the patient’s interview. On
the other hand, extract-based diagnostic tests are unable to
distinguish a genuine sensitization from cross-reactivity due to
poor standardization and high sequence homology. Component-
resolved diagnostics (45, 46) and prospective symptom recording
via eDiary application were proposed as potential solutions to
support the clinician in the detection of genuine sensitizations
and confirmation of their clinical relevance (47). However,
both tools generate rather large data sets which are difficult
to work with in a busy clinical setting, providing an optimal
opportunity for digitally facilitated and guideline-oriented
decision support. The strength of this particular approach
lies in a blended care approach combining the expertise
and experience of the doctor in personal visits with digital
monitoring support. Further, a looped design, facilitates a
continuous re-evaluation based on real-time patient-recorded
symptom data and information on the respective allergen
exposure. The physician plays a strong role in this CDSS
(named @IT-DSS) as it is customizable with regard to thresholds
for test positivity according to personal experience and local
environmental and epidemiological conditions (Figure 3). The
@IT-DSS has been tested in a clinical pilot and multicenter
study where the combination of face-to-face visits with
symptom monitoring via eDiary showed promising results in
terms of patient adherence, a common challenge for most
monitoring apps. Although the daily use of the app for
symptom and medication monitoring declined slowly over
time, the observed drop in adherence was significantly lower
than in other studies based on the spontaneous download
of apps from the respective app stores (47). Further results,
especially on the efficacy of the CDSS are expected to be
published soon.
DIGITAL DECISION SUPPORT FOR
ASTHMA CARE
A multitude of tools for asthma care have been developed,
ranging from reminder systems (48), monitoring apps (49,
50), smart devices (51, 52) up to comprehensive digital
care platforms (53). Although many of these technologies
deliver valuable information for clinical decision-making, not
all classify as a CDSS. Like for AR, also for asthma care
there is a great heterogeneity in concepts, user groups and
outcome assessments of digital health tools and CDSS (54).
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FIGURE 3 | General concept of a guideline-based, looped and customizable clinical decision support system. Thresholds can be adapted by the clinician according
to his/her clinical experience and local characteristics in a blended care setting. Patient and environmental data are continuously collected, and updated reports
created. Adapted from Matricardi et al. (33).
Interestingly, the impact of these systems seems to depend
on the targeted user group. A systematic review on CDSS
impact, when used by healthcare professionals with expertise
in asthma management, reported a low effect on asthma
control, mainly due to very low usage rates. The usability
and user-centered design of CDSS are essential to achieve
a sufficient adoption and high impact of the technologies
(55). Similarly, a systematic review showed that CDSS are
effective in improving care of patients with asthma and
chronic obstructive pulmonary disease (COPD) when used in
primary health care settings (56). The authors further underline
that despite the positive impacts assessed in the randomized,
controlled trials, the effects of the CDSS on user workload
and efficiency, safety, costs of care, provider, and patient
satisfaction remain understudied (56). Recently, the use of
an electronic Asthma Management System (eAMS) improved
the quality of asthma care for adult patients in a 2-year
interrupted time-series study of usual care (year 1) vs. eAMS
(year 2) at three Canadian primary care sites (34). However,
further work on the identification of facilitators and barriers for
uptake by clinicians is being done and randomized controlled
trials assessing patients’ outcomes are still needed (34). Other
promising concepts, such as the myAirCoach system (53),
combine the use of a smart adapter for inhalers, with an
indoor air-quality monitor, a physical activity tracker, a portable
spirometer, a fraction exhaled nitric oxide device, and an app in
one platform. Although these tools have only been tested in a
small number of patients and not yet been included in a CDSS,
they collect valuable information for personalized decision-
making and it remains to be tested whether this concept can
potentially be scaled up for a broader adoption. In addition,
diagnostic approaches, such as serological multiplex tests for
allergen- and virus-triggered asthma (57) could deliver important
information for personalized asthma management, potentially
supported by a CDSS.
DIGITAL SUPPORT TOOLS FOR OTHER
ALLERGIC DISEASES
Several other tools have been developed to digitally augment
allergy care namely supporting diagnosis and management in
a primary care setting (58) or among junior clinicians (59), as
well as for specific allergic diseases such as drug hypersensitivity
(60–63), food allergies (64) and urticaria (65).
Allergy Management Support for Primary
Care
Based on literature review, focused interviews and testing in
primary as well as secondary care patients, a group of allergists,
dermatologists, GP and researchers from the Netherlands
developed a guideline-based allergy management support system
(AMSS) for allergy diagnosis and management in primary care
settings (58). The AMSS interprets data from a 12-item multiple
choice questionnaire with test results for allergen-specific IgE
antibodies. After applying the algorithm to data from 118
patients, the authors identified 150 different diagnostic categories
of AR, asthma, atopic dermatitis, anaphylaxis, food allergy,
hymenoptera allergy, and other allergies. When comparing
the AMSS outcomes with specialists’ recommendations as
gold standard, an agreement of 69.2% (CI 67.2–71.2) was
observed. In a clinical study on the implementation of the
system, GPs showed a significant improvement in allergy
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diagnosis and reported a positive impact of the system
on their clinical routine. However, the decision-making on
medication and referral has not been affected by the use of the
AMSS (66).
Diagnostic Interpretation Support
With the aim of supporting the diagnostic decisions on
AR among junior clinicians, a group of developers and
researchers from India established a CDSS based on the
clinical history and intradermal test results for 40 locally
relevant allergens. The authors developed and validated the
algorithm with data from 857 allergic patients and found
that the CDSS differentiated the presence or absence of AR
with an accuracy of 88.31% compared to the opinion of
allergy experts (gold standard). Further, the study assessed the
preferred CDSS model among junior clinicians who indicated
to prefer a rule-based approach for its intelligible knowledge
model (59).
Drug Hypersensitivities
Several mobile applications have been created to assist doctors
in the assessment of the causality, severity and preventability
of adverse drug reactions (60). The use of a clinical decision
support tool for non-allergists evaluating inpatients reporting
penicillin allergy led to a twofold increase in penicillin or
cephalosporin prescription compared to standard care (61).
Similarly, a significant number of children could be de-labeled
from penicillin allergy by primary care physicians following an
algorithm for risk stratification and further work-up, including
a telemedicine screening and single dose oral challenge (62).
A systematic review has been conducted to assess the potential
of computerized physician order entry systems with built-in
clinical decision support for an improved management of drug
hypersensitivity. The authors concluded, that the heterogeneity
in recording of adverse events represents a considerable challenge
for a unified interpretation of recorded data (63, 67). Further,
an alert fatigue has been described in several studies due to a
lack of alert specificity (67). As the alert systems are built to
point out any potentially dangerous drug interaction of allergenic
threat for patient safety, these alerts can become very numerous
considering the large variety of drugs and potential interactions.
Of course, clinical considerations of the individual patient need
to be considered as well and studies showed that clinicians
tend to ignore alerts in many cases. The frequent signaling of
potential hazards may cause a certain fatigue among users which
limits the possible impact of the system. Again, user-centered
design seems to be essential, considering a balance between
safety and alert frequency. This challenging task will need to
be addressed in future developments and studies, recognizing
particular needs, such as the support of primary care physicians
in the management of chronic diseases where polypharmacy is
the norm (68).
Food Allergies
An initiative to support pediatricians in the work-up of patients
reporting allergic symptoms related to foods has been created
consolidating complex guidelines for the management of food
allergies into five key steps. The development of the Food Allergy
Support Tool further involved rapid-cycle improvement methods
to create a CDSS facilitating food allergy management in a
primary care setting. Interestingly a pilot evaluation showed that
physicians were uncertain about the benefits of the system. The
authors name the necessary active user initiation as a potential





The strategy of making large data sets easily intelligible for
specialized but also non-specialized healthcare providers, opens
new opportunities for an efficient use of medical resources.
In several countries, the numbers of specialized allergists are
declining while there is a continuous increase of patients needing
allergy care. This gap raises the pressure on primary health care
workers and digital technologies represent a valuable tool for an
intelligent distribution of work force and knowledge. This should
ideally be supported by a digitally enabled availability of context-
specific decision support, as guidelines may vary according to
the clinical setting (primary care vs. specialist vs. tertiary care).
By raising awareness at important community healthcare points
such as pharmacies, an early identification of patients eligible
for AIT can be fostered, always keeping in mind, that several
significant barriers for the implementation of AIT still need to be
overcome (69). Early interventions such as allergen avoidance can
be efficiently implemented already at first contact with a primary
health care physician and advice from specialists can be facilitated
via remote consultations. But even beyond the purely medical
field, a concept of community medicine can be revitalized via
the use of comprehensive digital platforms. Patients can manage
the access rights to their data and decide to share or donate
them for research purposes or community projects, collaborating
with environmental monitoring and public health institutions, a
broad network of information is available for exploitation with
the respective decision support tools.
Several of the above-mentioned support systems include
the retrieval and storage of patient- and/or sensor-generated
monitoring data. This provides the attending physician with
comprehensive data sets for the evaluation of disease control
during regular follow-up visits. Prospectively collected data on
treatment adherence, quality of life, disease-specific symptoms
and objective parameters such as sensor-recorded heart rate
or sleep quality can be easily assessed in visual summaries
or standardized scores (e.g., symptom and medication scores)
which are generated in an automated fashion. At first sight,
these digital platforms seem to clearly outperform traditional
approaches. However, the impact of their use on diagnostic
precision, treatment efficacy, safety, quality of life and treatment
costs needs to be objectivized and studied in more detail with
regard to allergic diseases as it has been already done in other
specialties and areas of medical care (70–73).
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PERSPECTIVES
In summary, digital technologies offer a vast potential to support
clinicians in their actions for prevention, diagnosis, treatment,
and monitoring of allergic diseases. Many different concepts
are under development and in different validation stages, which
opens a promising perspective for the next years. However,
no tools are currently commercially available yet and time-
consuming evaluations are necessary to enable the registration
as a medical product. As CDSS may have a significant impact
on key decisions for patient care, they need to be rigorously
tested for applicability and usability in order to support clinicians
in making the best choices for their patients. In addition, the
interoperability with existing software systems and a smooth
integration in clinical routine are significant challenges for
a successful implementation. More real-life experiences and
clinical studies will need to be conducted in order to extend our
knowledge and foster a solid adoption in of digital support tools
in the clinical routine.
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